The strong first-year Ryoncil revenue validates commercial execution and supports the pipeline expansion into larger indications (adult SR-aGvHD, DMD, CLBP, LVAD). Traders should watch for enrollment updates in the adult SR-aGvHD trial and the DMD trial, as well as the CLBP Phase 3 data readout and the modular BLA review for rexlemestrocel-L. The CAR technology license adds optionality in autoimmune indications but is early-stage.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $14.55entry
- T+1 · 4mo ago −2.61%α −3.32% · $14.17
- T+5 · 3mo ago +7.35%α +3.73% · $15.62
- T+20 · 3mo ago +24.95%α +20.98% · $18.18
- T+60 · 25d ago −15.60%α −18.07% · $12.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, with US$103M cash at quarter end. Operational milestones include commencement of the adult SR-aGvHD label extension trial, IND clearance for Duchenne muscular dystrophy, and achievement of the 300-patient enrollment target in the pivotal Phase 3 chronic low back pain trial. The company also received a BLA filing number for rexlemestrocel-L in LVAD patients and acquired a CAR technology license.
Key Facts
- Ryoncil net revenue Q4 FY2026: US$36 million
- Ryoncil net revenue first full year post-FDA approval: US$115 million (US$66.5M in H2)
- Cash and cash equivalents at June 30, 2026: US$103 million
- Net operating cash spend full year: US$43.8 million (US$13.4M in H2)
- Registration trial for Ryoncil label extension into adults with SR-aGvHD commenced and enrolling
- FDA IND clearance received for Ryoncil in ambulatory children aged 5-9 with Duchenne muscular dystrophy
- Target of at least 300 patients treated in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain achieved
- BLA filing number received from FDA for rexlemestrocel-L in prevention of GI bleeding in LVAD patients
- Acquired exclusive worldwide license to a patented CAR technology platform for MSC enhancement
Financial Impact
Ryoncil generated US$115M in annual net revenue in its first full launch year; operating cash burn of US$43.8M; cash position of US$103M provides ~11 quarters of runway at current burn rate
Risk Factors
- Clinical trial enrollment and data readout risks for adult SR-aGvHD, DMD, and CLBP trials
- Regulatory approval uncertainty for rexlemestrocel-L BLA in LVAD indication
- Competition from other cell therapies and biologics in inflammatory diseases
- Cash burn may require future financing if revenue growth slows or pipeline milestones are delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000072 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000072 |
| Document: 0001345099-26-000072-index-headers.html | 0001345099-26-000072 |
| Document: 0001345099-26-000072-index.html | 0001345099-26-000072 |
| Document: 0001345099-26-000072.txt | 0001345099-26-000072 |
Track record
25 reports on MESO
7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +15.67% at T+5 after the Jul 9, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers